Source: Annual Congress 2004 - Pulmonary fibrosis - new insights
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Fujimoto, Y. Ishii, T. Fukuda (Mibu, Japan). Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice. Eur Respir J 2004; 24: Suppl. 48, 3019

Member's Comments

No comment yet.

Related content which might interest you: Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Bradykinin phosphorylates ERK1/2 through epidermal growth factor receptor transactivation in human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 341s Year: 2005 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Tyrosine kinase inhibition of human pulmonary fibroblast migration Source: Eur Respir J 2005; 26: Suppl. 49, 101s Year: 2005 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Gene transfer of a β-adrenergic receptor kinase inhibitor up-regulated levels of β-adrenergic receptor and cAMP in asthmatic murine lung Source: Eur Respir J 2005; 26: Suppl. 49, 580s Year: 2005 Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Source: Eur Respir J 2007; 29: 976-985 Year: 2007 The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 SD-208 an orally active TGF-β1 receptor antagonist inhibits TGF-β1 induced progressive lung fibrosis in rat Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003 Protein tyrosine phosphatase-alpha (PTPa) promotes profibrotic responses in lung fibroblasts Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Inhibitory effects of the IL-6 receptor superantagonist SANT7 on MAP kinase phosphorylation and cell proliferation induced by IL-6 and TGF-beta1 in human lung fibroblasts Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021